PPBT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Purple Biotech Ltd (PPBT) is not a strong buy at this time for a beginner investor with a long-term strategy. While the company has ongoing developments in its CAPTN-3 platform and a Buy rating from analysts, its financial performance remains weak with no revenue growth and significant net losses. Additionally, technical indicators and options data do not suggest a strong upward momentum, and there are no recent Intellectia Proprietary Trading Signals to support a buy decision.
The MACD is positive and contracting, indicating a neutral to slightly bullish trend. RSI is neutral at 51.987, and moving averages are converging, showing no clear directional trend. The stock is trading near its pivot point of 4.436, with resistance levels at 4.871 and 5.14, and support levels at 4 and 3.731.
The company has formed a scientific advisory board to advance its CAPTN-3 antibody platform, and analysts maintain a Buy rating with a price target of $30, indicating long-term potential.
Financial performance is weak, with no revenue growth and significant net losses. The stock has a 60% chance to decline in the next week, and options data shows no significant trading activity or bullish sentiment.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net loss of -$23.54 million, which increased by 5642.68% YoY. EPS remained negative at -0.01, with no gross margin improvement.
H.C. Wainwright maintains a Buy rating but lowered the price target from $34 to $30, citing a discounted cash flow analysis. The firm expects updates on investigational new drug submissions and Phase 1 plans throughout 2026.
